UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3)

Ophthalmology (Rochester, Minn.), 2017-01, Vol.124 (1), p.53-60

2017

Volltextzugriff (PDF)

Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study

Ophthalmology (Rochester, Minn.), 2015-12, Vol.122 (12), p.2423-2431

2015

Volltextzugriff (PDF)

Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study

Ophthalmology (Rochester, Minn.), 2014-02, Vol.121 (2), p.475-483

2014

Volltextzugriff (PDF)

Maintenance of Long-Lived Plasma Cells and Serological Memory Despite Mature and Memory B Cell Depletion during CD20 Immunotherapy in Mice

The Journal of immunology (1950), 2008-01, Vol.180 (1), p.361-371

2008

Volltextzugriff (PDF)

Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study

Cornea, 2016-06, Vol.35 (6), p.741-748

2016

Volltextzugriff (PDF)

Impact of Leukocyte Function-Associated Antigen-1 Blockade on Endogenous Allospecific T Cells to Multiple Minor Histocompatibility Antigen Mismatched Cardiac Allograft

Transplantation, 2015-12, Vol.99 (12), p.2485-2493

2015

Volltextzugriff (PDF)

HDAC6 Deacetylase Activity Links the Tubulin Cytoskeleton with Immune Synapse Organization

Immunity (Cambridge, Mass.), 2004-04, Vol.20 (4), p.417-428

2004

Volltextzugriff (PDF)

The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs

Investigative ophthalmology & visual science, 2011-05, Vol.52 (6), p.3174-3180

2011

Volltextzugriff (PDF)

A Phase 2 Randomized, Double-Masked, Placebo-Controlled Study of a Novel Integrin Antagonist (SAR 1118) for the Treatment of Dry Eye

American journal of ophthalmology, 2012-06, Vol.153 (6), p.1050-1060.e1

2012

Volltextzugriff (PDF)

Small Molecule Antagonist of Leukocyte Function Associated Antigen-1 (LFA-1): Structure−Activity Relationships Leading to the Identification of 6-((5S,9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic Acid (BMS-688521)

Journal of medicinal chemistry, 2010-05, Vol.53 (9), p.3814-3830

2010

Volltextzugriff (PDF)

Total Synthesis of LFA-1 Antagonist BIRT-377 via Organocatalytic Asymmetric Construction of a Quaternary Stereocenter

Organic letters, 2005-03, Vol.7 (5), p.867-870

2005

Volltextzugriff (PDF)

The involvement of lipid rafts in the regulation of integrin function

Journal of cell science, 2002-03, Vol.115 (Pt 5), p.963-972

2002

Volltextzugriff (PDF)

Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases

Medicinal research reviews, 2002-03, Vol.22 (2), p.146-167

2002

Volltextzugriff (PDF)

Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR)

Investigative ophthalmology & visual science, 2010-10, Vol.51 (10), p.5198-5204

2010

Volltextzugriff (PDF)

Design, Synthesis, and Functional Evaluation of Leukocyte Function Associated Antigen‑1 Antagonists in Early and Late Stages of Cancer Development

Journal of medicinal chemistry, 2013-02, Vol.56 (3), p.735-747

2013

Volltextzugriff (PDF)

LFA‐1 (CD11a) as a Therapeutic Target

American journal of transplantation, 2006-01, Vol.6 (1), p.27-36

2006

Volltextzugriff (PDF)

Crystal structure of isoflurane bound to integrin LFA-1 supports a unified mechanism of volatile anesthetic action in the immune and central nervous systems

The FASEB journal, 2009-08, Vol.23 (8), p.2735-2740

2009

Volltextzugriff (PDF)

Binding Site Elucidation of Hydantoin-Based Antagonists of LFA-1 Using Multidisciplinary Technologies: Evidence for the Allosteric Inhibition of a Protein−Protein Interaction

Journal of the American Chemical Society, 2001-06, Vol.123 (24), p.5643-5650

2001

Volltextzugriff (PDF)

Update 2011: leflunomide in rheumatoid arthritis – strengths and weaknesses

Current opinion in rheumatology, 2011-05, Vol.23 (3), p.282-287

2011

Volltextzugriff (PDF)

LFA-1 Antagonists as Agents Limiting Human Immunodeficiency Virus Type 1 Infection and Transmission and Potentiating the Effect of the Fusion Inhibitor T-20

Antimicrobial Agents and Chemotherapy, 2009-11, Vol.53 (11), p.4656-4666

2009

Volltextzugriff (PDF)

Leukotoxin Kills Rodent WBC by Targeting Leukocyte Function Associated Antigen 1

Comparative medicine, 2013-08, Vol.63 (4), p.331-337

2013

Volltextzugriff (PDF)

Contributions of molecular binding events and cellular compliance to the modulation of leukocyte adhesion

Journal of cell science, 2003-06, Vol.116 (Pt 12), p.2531-2539

2003

Volltextzugriff (PDF)

Allosteric LFA-1 Inhibitors Modulate Natural Killer Cell Function

Molecular pharmacology, 2009-02, Vol.75 (2), p.355-362

2009

Volltextzugriff (PDF)

Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118)

Journal of ocular pharmacology and therapeutics, 2013-05, Vol.29 (4), p.395-402

2013

Volltextzugriff (PDF)

Beyond calcineurin inhibitors: emerging agents in kidney transplantation

Current opinion in nephrology and hypertension, 2013-11, Vol.22 (6), p.689-697

2013

Volltextzugriff (PDF)

1 – 25 von 988

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(937)
Mit Volltextzugriff
(779)

Publikationsform

Artikel
(986)
Buchkapitel
(2)

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(780)
Life Sciences & Biomedicine
(753)
Humans
(643)
Animals
(476)
Lymphocyte Function-Associated Antigen-1 - Metabolism
(378)
Biological And Medical Sciences
(372)
Immunology
(359)
Mice
(326)
Cell Adhesion - Drug Effects
(256)
Lymphocyte Function-Associated Antigen-1 - Immunology
(248)
Medical Sciences
(206)
Cells, Cultured
(201)
Lymphocyte Function-Associated Antigen-1 - Physiology
(191)
Male
(189)
Intercellular Adhesion Molecule-1 - Metabolism
(180)
Fundamental And Applied Biological Sciences. Psychology
(177)
Female
(172)
Cell Biology
(145)
Antibodies, Monoclonal - Pharmacology
(140)
T-Lymphocytes - Drug Effects
(129)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3)

Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study

Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study

Maintenance of Long-Lived Plasma Cells and Serological Memory Despite Mature and Memory B Cell Depletion during CD20 Immunotherapy in Mice

Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study

Impact of Leukocyte Function-Associated Antigen-1 Blockade on Endogenous Allospecific T Cells to Multiple Minor Histocompatibility Antigen Mismatched Cardiac Allograft

HDAC6 Deacetylase Activity Links the Tubulin Cytoskeleton with Immune Synapse Organization

The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs

A Phase 2 Randomized, Double-Masked, Placebo-Controlled Study of a Novel Integrin Antagonist (SAR 1118) for the Treatment of Dry Eye

Small Molecule Antagonist of Leukocyte Function Associated Antigen-1 (LFA-1): Structure−Activity Relationships Leading to the Identification of 6-((5S,9R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic Acid (BMS-688521)

Total Synthesis of LFA-1 Antagonist BIRT-377 via Organocatalytic Asymmetric Construction of a Quaternary Stereocenter

The involvement of lipid rafts in the regulation of integrin function

Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases

Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR)

Design, Synthesis, and Functional Evaluation of Leukocyte Function Associated Antigen‑1 Antagonists in Early and Late Stages of Cancer Development

LFA‐1 (CD11a) as a Therapeutic Target

Crystal structure of isoflurane bound to integrin LFA-1 supports a unified mechanism of volatile anesthetic action in the immune and central nervous systems

Binding Site Elucidation of Hydantoin-Based Antagonists of LFA-1 Using Multidisciplinary Technologies: Evidence for the Allosteric Inhibition of a Protein−Protein Interaction

Update 2011: leflunomide in rheumatoid arthritis – strengths and weaknesses

LFA-1 Antagonists as Agents Limiting Human Immunodeficiency Virus Type 1 Infection and Transmission and Potentiating the Effect of the Fusion Inhibitor T-20

Leukotoxin Kills Rodent WBC by Targeting Leukocyte Function Associated Antigen 1

Contributions of molecular binding events and cellular compliance to the modulation of leukocyte adhesion

Allosteric LFA-1 Inhibitors Modulate Natural Killer Cell Function

Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118)

Beyond calcineurin inhibitors: emerging agents in kidney transplantation

Suchergebnisse filtern